Kura Oncology, Inc. (NASDAQ:KURA) Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC grew its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 463.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 597,810 shares of the company's stock after buying an additional 491,700 shares during the period. Renaissance Technologies LLC owned 0.77% of Kura Oncology worth $5,207,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Harbor Advisors LLC purchased a new stake in Kura Oncology during the fourth quarter valued at about $87,000. E Fund Management Co. Ltd. purchased a new stake in shares of Kura Oncology during the 4th quarter worth about $90,000. Corient Private Wealth LLC acquired a new stake in Kura Oncology during the 4th quarter worth approximately $109,000. Teacher Retirement System of Texas increased its position in Kura Oncology by 19.9% during the 4th quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company's stock worth $120,000 after purchasing an additional 2,285 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in Kura Oncology in the fourth quarter valued at approximately $127,000.

Kura Oncology Stock Down 0.3 %

Shares of NASDAQ:KURA traded down $0.02 during midday trading on Friday, reaching $6.41. The company had a trading volume of 218,905 shares, compared to its average volume of 1,143,243. Kura Oncology, Inc. has a one year low of $5.41 and a one year high of $23.48. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The stock has a market capitalization of $517.95 million, a P/E ratio of -2.71 and a beta of 0.83. The stock's fifty day moving average price is $6.91 and its 200-day moving average price is $10.13.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.43. The company had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million. Equities research analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the business's stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares in the company, valued at $694,551.11. The trade was a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Thomas James Doyle sold 4,949 shares of the firm's stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the transaction, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock worth $92,307 over the last quarter. 6.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms have recently issued reports on KURA. BTIG Research lowered shares of Kura Oncology from a "buy" rating to a "neutral" rating in a research report on Thursday, February 6th. JMP Securities reiterated a "market outperform" rating and issued a $28.00 price target on shares of Kura Oncology in a report on Thursday, February 6th. UBS Group reduced their price objective on Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Cantor Fitzgerald upgraded Kura Oncology to a "strong-buy" rating in a report on Tuesday, March 4th. Finally, Scotiabank decreased their price target on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $25.50.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.